HemCon Expands Reach with New Licensing Agreement

HemCon has signed an agreement with Institute of Technology Sligo, Ireland, to license a controlled release hydrogen peroxide technology. The technology has broad spectrum antibacterial and antiseptic properties and has particular promise as a treatment for fungal nail infection.

Onychomycosis, or toenail fungus, affects six to eight percent of the adult U.S. population. Because the infection is embedded within the nail and is difficult to reach, treatment remains a challenge. Most therapies require systemic antifungal medications delivered orally.

HemCon has the right to directly commercialize or sub-license these technologies globally.

The comments are closed.